Keywords: atacand, cuts, diabetes, risk, hf, patients, data

Atacand cuts diabetes risk in HF patients

Article | 11 July 2005

Print This

Data from three trials in the CHARM (Candesartan in Heart Failure - Assessment of Reduction in Mortality and Morbidity) program, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in